Apellis Pharmaceuticals, Inc.

    Jurisdiction
    United States
    LEI
    254900HS0ZFRXXSB9D42
    ISIN
    US03753U1060 (APLS)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €647.82M
    Gross margin
    83.7%
    EBIT
    -€163.15M
    EBIT margin
    -25.2%
    Net income
    -€195.87M
    Net margin
    -30.2%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €771.32M +19.1% -€84.13M -57.1%
    €942.21M +22.2% €48.99M -158.2%
    €1.12B +18.8% €133.80M +173.1%

    Dividends

    No dividend payouts

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Chopas James George VP/Chief Accounting Officer -548 $28.08 -$15.39K
    Francois Cedric Chief Executive Officer -225K $28.23 -$6.35M
    Watson David O. General Counsel -5K $27.80 -$139.00K

    Earnings Calls

    Latest earnings call: May 7, 2024

    Add to watchlist

    Notifications